Invest In Vincere Biosciences
12/06/2023 12:04
June 12 (Reuters) - Hanall Biopharma Co Ltd 009420.KS :
* HANALL BIOPHARMA AND DAEWOONG PHARMACEUTICAL CO-INVEST IN
VINCERE BIOSCIENCES FOR COLLABORATIVE OPPORTUNITIES IN
PARKINSON'S DISEASE
Source text for Eikon: ID:nPn7Kl9R3a
Further company coverage: 009420.KS
Recent news on Hanall Biopharma
See all newsQ2 2026 Operating Profit Up 567.4% QoQ, 388.5% YoY To Won 5.60 Billion
Brief: Hanall Biopharma Co Icc Rules Licensing Deal With Harbour Biomed Continues To Be Effective
Brief: Hanall Biopharma Q1 Operating Profit 839 Million Won, Swings To Profit From Year Earlier
Immunovant falls as drug for thyroid eye disease fails late-stage trials
Immunovant falls as eye disease therapy fails in late-stage studies